June 02, 2021

After One Year in Market, Lens Demonstrates a Measurable Impact on
Keeping and Attracting Patients with Presbyopia to Contact Lenses

SAN RAMON, Calif., June 2, 2021—Eye care professionals (ECPs) are leveraging CooperVision Biofinity® toric multifocal contact lenses to fit more of their patients with presbyopia in contact lenses, keeping and reengaging people in the category. In just one year since the introduction of Biofinity® toric multifocal in the U.S. marketplace, new data from GfK reveals that 50% of patients fit in the lens have been new or lapsed contact lens wearers1.

“We know that astigmatism is a very common refractive error for people of all ages2, including middle-aged and older adults who are presbyopes—and the rate of contact lens wear decreases significantly after the age of 403. Over the past year, we have created substantial opportunity for optometry practices to recapture lost revenue while also giving these patients the quality of vision and lifestyle that they deserve,” said Michele Andrews, OD, Vice President of Professional & Government Affairs, Americas, CooperVision.

Biofinity® toric multifocal provides ECPs with an option for transitioning their existing toric contact lens wearers as they reach presbyopia. In fact, the GfK data shows that of the Biofinity® toric multifocal wearers who are refit from a different lens, the majority come from torics1.

“Toric contact lens wearers who are happy with their comfort and vision would like to remain that way beyond the onset of presbyopia,” said Dr. Andrews. “In the past, many of these wearers—and their ECPs—have been frustrated with the inconsistent performance of toric multifocal contact lenses, and have been forced to make compromises. Now, Biofinity® toric multifocal has a 93% success rate on initial fitting when using the fitting guide4. This lens has truly changed the game.”

According to GfK, the U.S. multifocal contact lens segment continues to develop, growing by 4% in Q4 2020 versus the previous year1. Accelerating adoption of Biofinity® toric multifocal since its launch in May 2020 helped enable multifocal segment growth, despite the challenges of the COVID-19 pandemic.

Biofinity® toric multifocal combines the comfort and proven optical designs of Biofinity® toric—the most prescribed toric lens on the market5—and Balanced Progressive® Technology from Biofinity® multifocal that has four distinct ADD powers for more accurate fitting. Like all Biofinity® silicone hydrogel lenses, Biofinity® toric multifocal features CooperVision’s Aquaform® Technology, which  offers superb breathability and higher moisture content to keep eyes comfortable and healthy.

CooperVision’s made-to-order advantage results in more than 205,000 prescription options6 to ensure eye care professionals have the lens they need for each individual patient, resulting in the right fit, the first time. Fitting is even easier with the toric and multifocal fitting calculator in CooperVision’s OptiExpert® app7, which is free to download in the App Store and Google Play, or can be accessed on the web.

Biofinity® toric multifocal lenses are available in sphere powers from +10.00 to -10.00 (0.50 steps after +/-6.00D), with cylinder powers from -0.75 to -5.75 (0.50 steps),  axis of 5 degrees to 180 degrees in 5-degree steps, and ADD powers of +1.00, +1.50, +2.00, and +2.50, with each ADD available in a D and N lens.

For more information, visit https://coopervision.com/practitioner/only-biofinity-toric-multifocal.


# # #

GfK Market Intelligence: US Contact Lens FITS Tracking, Q4 2020

Hashemi H, et al. J Curr Ophthalmol. 2018;30(1):3-22

Morgan PB., Efron N, Woods CA. An international survey of contact lens prescribing for presbyopia. N Clin Exp Optom. 2011 Jan;94(1):87-92

CVI Data on file 2018. Non-dispensing, subject masked, randomized, bilateral, cross-over short-term clinical evaluation. 27 astigmatic, presbyopic soft CL wearers at 2 sites (UK & US) fitted using CVI fit guide

5 CVI data on file, 2019. US industry reports and internal estimates

CVI data on file 2019. Based on total number of prescription option combinations manufactured (for sphere, cylinder, axis and add – including D & N combinations)

7 Luensmann D et al. Toric lens fitting success supported by an online fitting App. Poster to be presented at NCC/BCLA 2020.]

About CooperVision
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.

About CooperCompanies
CooperCompanies (“Cooper”) is a global medical device company public traded on NYSE (NYSE: COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.

Media Contact
Heather Kowalczyk
McDougall Communications for CooperVision, Inc.
heather@mcdougallpr.com or +1-585-434-2148